Baylor Research Institute

Schering Corporation

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Université Paris Est Creteil Val De Marne

Gerard Zurawski

Sandra M Zurawski

Jacques F Banchereau

SangKon Oh

Anne-Laure Flamar

Daniel M Gorman

Yves Levy

Sangkon Oh

Eynav Klechevsky

Robert A Kastelein

J Fernando Bazan

Dapeng Li

Monica Montes

Keiko Akagawa

Peter Klucar

Terrill K McClanahan

Joseph H Phillips

Lewis L Lanier

Gosse Jan Adema

John Ford

Hyemee Joo

Linde Meyaard

Sriram Balasubramanian

Keith D Brown

Timothy R Mosmann

Hideki Ueno

Janice A Culpepper

Andrew McKenzie

Amanda Cobb

Warren Dang

Holly Mead

Ling Ni

Helene Dutartre

Timothy K Mosmann

Sandra M Kurawski

Bob Kane

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

Vaccines against HPV and HPV-related diseases

Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis

The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

Methods and compositions for treating autoimmune and inflammatory conditions

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Fusion proteins comprising an anti-CD40 antibody and cancer antigens

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Nucleic acids encoding anti-CD40 antibodies

Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Methods and compositions for treating and preventing HIV

Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides

Anti-CD40 antibodies

Growing community of inventors

Midlothian, TX, United States of America

Gerard Zurawski